Efficacy and safety of avelumab plus axitinib (A plus Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.

被引：7

作者：

Tomita, Yoshihiko ^{[1
]}

Motzer, Robert J. ^{[2
]}

Choueiri, Toni K. ^{[3
,4
]}

Rini, Brian I. ^{[5
]}

Miyake, Hideaki ^{[6
]}

Uemura, Hirotsugu ^{[7
]}

Albiges, Laurence ^{[8
]}

Fujii, Yosuke ^{[9
]}

Umeyama, Yoshiko ^{[9
]}

Wang Jing ^{[10
]}

Mariani, Mariangela ^{[11
]}

Schmidinger, Manuela ^{[12
]}

机构：

[1] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Harvard Med Sch, Boston, MA 02115 USA

[5] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[6] Hamamatsu Univ, Sch Med, Dept Urol, Hamamatsu, Shizuoka, Japan

[7] Kindai Univ, Fac Med, Dept Urol, Osaka, Japan

[8] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[9] Pfizer R&D Japan, Tokyo, Japan

[10] Pfizer Inc, Cambridge, MA USA

[11] Pfizer SRL, Milan, Italy

[12] Med Univ Vienna, Vienna, Austria

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期

关键词：

D O I：

10.1200/JCO.2021.39.6_suppl.301

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

301

引用

页数：2

共 50 条

[21] Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
Tomita, Y.
Larkin, J.
Venugopal, B.
Haanen, J.
Kanayama, H.
Eto, M.
Grimm, M-O
Fujii, Y.
Umeyama, Y.
Huang, B.
Mariani, M.
di Pietro, A.
Choueiri, T. K.
ESMO OPEN, 2022, 7 (05)
[22] JAVELIN renal 101: A randomized, phase III study of avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)
Motzer, R. J.
Penkov, K.
Haanen, J. B. A. G.
Rini, B. I.
Albiges, L.
Campbell, M. T.
Kollmannsberger, C. K.
Negrier, S.
Uemura, M.
Lee, J. L.
Gurney, H.
Berger, R.
Schmidinger, M.
Larkin, J.
Atkins, M. B.
Wang, J.
Robbins, P. B.
Chudnovsky, A.
Di Pietro, A.
Choueiri, T. K.
ANNALS OF ONCOLOGY, 2018, 29 : 724 - 724
[23] Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Motzer, Robert J.
Penkov, Konstantin
Haanen, John
Rini, Brian
Albiges, Laurence
Campbell, Matthew T.
Venugopal, Balaji
Kollmannsberger, Christian
Negrier, Sylvie
Uemura, Motohide
Lee, Jae L.
Vasiliev, Aleksandr
Miller, Wilson H., Jr.
Gurney, Howard
Schmidinger, Manuela
Larkin, James
Atkins, Michael B.
Bedke, Jens
Alekseev, Boris
Wang, Jing
Mariani, Mariangela
Robbins, Paul B.
Chudnovsky, Aleksander
Fowst, Camilla
Hariharan, Subramanian
Huang, Bo
di Pietro, Alessandra
Choueiri, Toni K.
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1103 - 1115
[24] Exposure-response (E-R) analysis of efficacy for avelumab in combination with axitinib in patients with advanced renal cell carcinoma (aRCC) in JAVELIN Renal 101.
Bello, Carlo
Brar, Satjit
Masters, Joanna C.
Khandelwal, Akash
Novakovic, Ana M.
Ruiz-Garcia, Ana
Hibma, Jennifer
CANCER RESEARCH, 2021, 81 (13)
[25] Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A plus Ax) vs sunitinib (S)
Choueiri, T. K.
Larkin, J. M. G.
Pal, S. K.
Motzer, R. J.
Venugopal, B.
Alekseev, B. Y.
Miyake, H.
Gravis, G.
Bilen, M. A.
Chudnovsky, A.
Ching, K. A.
Mariani, M.
Robbins, P. B.
Huang, B.
di Pietro, A.
Albiges, L.
ANNALS OF ONCOLOGY, 2019, 30 : 361 - 361
[26] Avelumab plus axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial
Motzer, Robert J.
Penkov, Konstantin
Uemura, Hirotsugu
Campbell, Matthew T.
Kollmannsberger, Christian K.
Lee, Jae-Lyun
Venugopal, Balaji
Van Den Eertwegh, Alfonsus
Negrier, Sylvie
Gurney, Howard
Albiges, Laurence
Berger, Raanan
Haanen, John
Rini, Brian I.
Larkin, James
Schmidinger, Manuela
Sandner, Robin
Wang, Jing
Di Pietro, Alessandra
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[27] Outcomes of patients who progressed while receiving avelumab plus axitinib (A plus Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101.
Albiges, Laurence
Voss, Martin H.
Rini, Brian I.
Gravis, Gwenaelle
Grimm, Marc-Oliver
Nathan, Paul D.
Bjarnason, Georg A.
Tomita, Yoshihiko
Penkov, Konstantin
McGregor, Bradley
Huang, Bo
Thomaidou, Despina
Mariani, Mariangela
Di Pietro, Alessandra
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[28] Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101)
Choueiri, Toni K.
Rini, Brian I.
Larkin, James M. G.
Bjarnason, Georg A.
Gravis, Gwenaelle
Gurney, Howard
Lee, Jae-Lyun
Keizman, Daniel
Haanen, John B. A. G.
Tomita, Yoshihiko
Uemura, Hirotsugu
Albiges, Laurence
Schmidinger, Manuela
Atkins, Michael B.
Mariani, Mariangela
Shnaidman, Michael
Di Pietro, Alessandra
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[29] JAVELIN renal 101: a phase 3 study of avelumab in combination with axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
Choueiri, Toni K.
Rini, Brian I.
Cosgriff, Thomas
Miyake, Hideaki
Vogelzang, Nicholas J.
Kannourakis, George
Mariani, Mariangela
Chiruzzi, Chiara
Albiges, Laurence
Haanen, John B.
Larkin, James
Atkins, Michael B.
Schmidinger, Manuela
Magazzu, Domenico
Di Pietro, Alessandra
Motzer, Robert J.
BJU INTERNATIONAL, 2016, 118 : 29 - 30
[30] Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab plus axitinib (A plus Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)
Albiges, L.
Rini, B. I.
Haanen, J. B. A. G.
Motzer, R. J.
Kollmannsberger, C. K.
Negrier, S.
Nole, F.
Bedke, J.
Bilen, M. A.
Nathan, P.
Tomita, Y.
Huang, B.
Ching, K. A.
Chudnovsky, A.
Robbins, P. B.
di Pietro, A.
Thomaidou, D.
Choueiri, T. K.
ANNALS OF ONCOLOGY, 2019, 30

← 1 2 3 4 5 →